Source: Legible Inc.
  • Legible (READ) has announced the integration of Open AI’s ChatGPT into its proprietary eBookstore search engine, LibrarianAI
  • Integrating ChatGPT into Legible’s eReading system provides a new way to access the two million eBooks in Legible’s catalogue
  • The Open Beta of Legible’s LibrarianAI launches in Q1 and LibrarianAI will be released in early Q2 as a membership service called Legible Unbound
  • Legible Inc is a book entertainment and media company that has developed a B2C eBook entertainment platform and a B2B eBook conversion and production service
  • Legible Inc. (READ) is up 5 per cent on the day, trading at C$0.105 per share at 12:45 pm ET

Legible (READ) has announced the integration of Open AI’s ChatGPT (Chat Generative Pre-Trained Transformer) into its proprietary eBookstore search engine, LibrarianAI.

Embedding this AI tool into Legible’s browser-based eReading system transforms book discovery, integrating ChatGPT’s legacy knowledge and capabilities and providing a whole new way to access the two million eBooks in Legible’s catalogue.

Preview of Legible LibrarianAI interface (Photo: Business Wire)

Preview of Legible LibrarianAI interface (Photo: Business Wire)

Legible’s LibrarianAI can converse fluently in any language and is being fine-tuned to provide swift, friendly, comprehensive responses and recommendations as well as information on any aspect of book content. Customers can ask questions about books, authors, and other topics related to literature and receive personalized results based on cumulative learning about their interests and choices, as well as links to Legible’s eBooks.

The Open Beta of Legible’s LibrarianAI launches in Q1. The LibrarianAI will be released in early Q2 as a membership service called Legible Unbound with several tiers and a free version with ads.

“At Legible, we anticipated the importance and transformative power of AI early in our development and began building our own AI product, originally called “The Librarian.” OpenAI’s ChatGPT has allowed us to accelerate this process,” stated Angela Doll, Legible’s Chief Publishing Officer. “As the world’s only browser-based eBookstore, Legible.com is ideally suited to use AI, combining worldwide web search with content from millions of eBooks.”

Legible’s LibrarianAI has the potential to turbocharge conversion rates, driving sales and engagement by helping customers find the perfect book to read and much more. Global eBook sales were estimated at US$20 billion in 2022 and are projected to reach US$32 billion by 2032 with a compound annual growth rate (CAGR) of 4.9 per cent from 2022 to 2032.

“AI is quickly being adopted worldwide and will soon be integrated into many aspects of our personal lives and business transactions. Legible is extremely well positioned to be part of that future thanks to our fully vectorized content and proprietary machine learning algorithms,” said Kaleeg Hainsworth, CEO of Legible.

“This is an exciting time for AI and the entire publishing industry, and we can’t wait to launch the LibrarianAI and Legible Unbound. Our goal is nothing less than to provide the most advanced eBook discovery and reading experience in the world.”

Legible Inc. is an AI-enriched eBook company providing eReading experiences to anyone with an internet-enabled device via two high-value verticals: legible.com, an AI-driven B2C eBook entertainment/education platform and Legible Publishing, a global B2B eBook conversion and production service specializing in multimedia digital publishing and eBook remediation for print-disabled and other accessibility-related audiences. 

Legible Inc. (READ) is up 5 per cent on the day, trading at C$0.105 per share at 12:45 pm ET.


More From The Market Online

@ the Bell: TSX recovers and S&P hits fresh high

Energy shares led enough of a rally to overcome industrials and tech losses to push the TSX to a positive end on Tuesday.

Pathologists group accepts Telo Genomics’ test for rare blood cancer

The College of American Pathologists accepts the Telo Genomics' (TSXV:TELO) submission of a test for a rare blood cancer.

Theralase adds cancer immunotherapy to potential revenue streams

Theralase Technologies' (TSXV:TLT) lead drug candidate, Rutherrin, enhanced cancer immunotherapy in a pre-clinical setting.